Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Secukinumab (enthesitis-associated arthritis) – Benefit assessment according to § 35a SGB V

Status
Status: Commission completed
Project no.
A22-69
Last updated

Report documents

  1. Extract of dossier assessment

    Secukinumab (enthesitis-associated arthritis) – Benefit assessment according to § 35a SGB V

    published on
    Document type
    PDF document, 288 kB, EN, not accessible
    Download file : Extract of dossier assessment (PDF document, 288 kB, EN, not accessible)

  2. Dossier assessment

    Secukinumab (enthesitis-associated arthritis) – Benefit assessment according to § 35a SGB V

    published on
    Document type
    PDF document, 480 kB, DE, not accessible
    Download file : Dossier assessment (PDF document, 480 kB, DE, not accessible)

Dossier assessment

Indication:

Alone or in combination with methotrexate for the treatment of active enthesitis-associated arthritis in patients aged 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy

Result of dossier assessment:

Added benefit not proven

Project details

Project no.
A22-69
Commission
Commission awarded on 12.07.2022 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Muscles, bones and joints
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Secukinumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

    Project no.
    A17-08
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Secukinumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)

    Project no.
    A15-20
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Secukinumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A15-53
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Secukinumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-78
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Secukinumab (non-radiographic axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-79
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Secukinumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-80
    Last updated

    Status: Commission completed

  7. Dossier assessment

    Secukinumab (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A22-68
    Last updated

    Status: Commission completed

  8. Dossier assessment

    Secukinumab (hidradenitis suppurativa) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-51
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page